Shikonin Attenuates Liver Ischemia‐Reperfusion Injury Through Direct Interaction With HMGB1 Protein
In general, our results suggest that shikonin is a promising natural candidate that directly targets HMGB1 to exert hepatoprotection for the development of clinical therapeutic anti-IR agents.
Authors
- Pingping Shen (ORCID: https://orcid.org/0000-0002-1072-784X)
- Guolong Li (ORCID: https://orcid.org/0000-0001-9402-5054)
- Jian Zhang (ORCID: https://orcid.org/0000-0002-4372-2826)
- Xuewa Jiang
- Libang Zhang
- Fang Liu
- Richa Raj
Institutions
- Xuzhou University of Technology (CN)
- China Pharmaceutical University (CN)
- Xuzhou Medical College (CN)
- State Administration of Traditional Chinese Medicine of the People's Republic of China (CN)
- Shaanxi University of Chinese Medicine (CN)
Publication Details
- Journal
- Journal of Gastroenterology and Hepatology
- Published
- 2026-01-07
- DOI
- https://doi.org/10.1111/jgh.70200
- Primary Topic
- Bioactive Compounds and Antitumor Agents
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Government of Jiangsu Province
- Natural Science Foundation of Jiangsu Province
- Qinglan Project of Jiangsu Province of China